Mycobacterium abscessus is a fast-growing non-tuberculous mycobacterium that can cause chronic lung disease leading to rapid decline in lung function. There are no FDA-approved therapies for this disease. To support the development of new treatments, an animal model of M. abscessus lung infection that is simple to implement and requires minimal resources is crucial to encourage broad adoption. We present a mouse model using the immunocompetent BALB/c strain, which is both widely available and cost-effective. Since BALB/c mice naturally clear M. abscessus infections, immunosuppression is necessary to sustain bacterial growth in the lungs. Once-weekly intraperitoneal injections of 250 mg/kg cyclophosphamide successfully induced M. abscessus proliferation during the acute phase, followed by stabilization characteristic of chronic infection. This model demonstrated the efficacy of imipenem—an antibiotic commonly used in clinical settings—by significantly reducing bacterial burdens, mirroring their effects in human cases. However, clofazimine, which is also used to treat this disease, was bacteriostatic. This cost-effective and accessible mouse model is suitable for diverse laboratory environments and provides a valuable tool for preclinical evaluation of treatments for M. abscessus lung disease.
A BALB/c mouse model of Mycobacterium abscessus lung infection based on once-weekly cyclophosphamide administration
Open Access
Call for papers – In Vitro Models of Human Disease to Inform Mechanism and Drug Discovery
We invite you to submit your latest research to our upcoming special issue: In Vitro Models of Human Disease to Inform Mechanism and Drug Discovery, coordinated by DMM Editor Vivian Li (The Francis Crick Institute, London, UK), alongside Guest Editors Austin Smith (University of Exeter, UK) and Joseph Wu (Stanford University School of Medicine, USA).The deadline for submitting articles is 6 October 2025.
The Company of Biologists Workshops
For the last 15 years, our publisher, The Company of Biologists, has provided an apt environment to inspire biology and support biologists through our Workshops series. Read about the evolution of the Workshop series and revisit JEB's experience with hosting the first Global South Workshop.
Read & Publish Open Access publishing: what authors say
We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
Fast & Fair peer review
Our sister journal Biology Open has recently launched the next phase of their Fast & Fair peer review initiative: offering high-quality peer review within 7 working days. To learn more about BiO’s progress and future plans, read the Editorial by Daniel Gorelick, or visit the Fast & Fair peer review page.
Propose a new Workshop for 2027
We are currently seeking proposals for Workshops to be held in 2027. As one of the scientific organisers of a The Company of Biologists Workshop, your involvement will be focused on interdisciplinary, cutting-edge science and promoting new partnerships and collaborations. We focus on the logistics. Are you thinking about proposing a topic for one of our Workshops? Apply by Friday 30 May 2025.
Social media
